Product Images Levetiracetam

The text appears to be a part of a figure caption containing information about the responder rate reduction in Study 1. A graph shows the percentage reduction in responder rate from the baseline. The treatment with Levetiracetam at a dose of 1000 mg/day and 2000 mg/day is compared to placebo, and the figure indicates the percentage of patients falling under each category. The text denotes the percentage reduction of 396% from the baseline. The information in the text is insufficient to provide a complete understanding of the context.*

Figure 2 shows the responder rate in Study 2 for patients treated with either Levetiracetam or placebo, with a 250% reduction from baseline. The graph displays the percentage of patients achieving the responder rate at different doses of Levetiracetam (100mg/day and 2000 mg/day) and a placebo group. The study found that Levetiracetam was statistically significant compared to the placebo.*

The text describes Figure 3 of a study. The figure shows the responder rate in Study 3 (-50% reduction from baseline) and the percentages of patients who responded to a placebo and a medication called Lewtiracstn. The medication was given at a dose of 5mg/day and the patients who received it had a statistically significant improvement compared to the placebo group.*

The figure shows the responder rate, which is the percentage of participants who achieved more than 50% reduction from baseline in their condition. The results suggest that the treatment (B) had a responder rate of 44.6%, which was statistically significant compared to placebo (10.6%). There were 97 participants in the placebo group.*

The image shows the responder rate in PGTC seizure frequency, with a 250% reduction from baseline per week. The graph includes results for patients taking placebo (N=84) and levetiracetam (N=79) and highlights a statistically significant difference between the two groups. No other information is available.*